{
    "Trade/Device Name(s)": [
        "RANDOX CALCIUM (Ca)"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K182042",
    "Predicate Device Reference 510(k) Number(s)": [
        "K083386"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CJY"
    ],
    "Summary Letter Date": "October 23, 2018",
    "Summary Letter Received Date": "",
    "Submission Date": "July 27, 2018",
    "Regulation Number(s)": [
        "21 CFR 862.1145"
    ],
    "Regulation Name(s)": [
        "Calcium test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Calcium"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "RX series analyzer",
        "RX daytona plus"
    ],
    "Method(s)/Technology(ies)": [
        "Arsenazo III colorimetric method"
    ],
    "Methodologies": [
        "Colorimetric determination"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Randox Calcium assay for quantitative measurement of calcium in serum, plasma, and urine using the Arsenazo III method on RX series analyzers.",
    "Indications for Use Summary": "Quantitative in vitro determination of calcium concentration in serum, plasma, and urine to aid diagnosis and treatment of parathyroid disease, bone diseases, and chronic renal failure.",
    "fda_folder": "Clinical Chemistry"
}